1
|
Scibetta S, Miceli M, Iuliano M, Stefanuto L, Carbone E, Piscopo P, Petrozza V, Romeo G, Mangino G, Calogero A, Gasperi T, Rosa P. In Vitro Evaluation of the Antioxidant Capacity of 3,3-Disubstituted-3H-benzofuran-2-one Derivatives in a Cellular Model of Neurodegeneration. Life (Basel) 2024; 14:422. [PMID: 38672695 PMCID: PMC11051253 DOI: 10.3390/life14040422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2024] [Revised: 03/18/2024] [Accepted: 03/19/2024] [Indexed: 04/28/2024] Open
Abstract
Oxidative stress represents a hallmark for many degenerative pathologies of the Central Nervous System. Throughout life, the constant pressure of noxious stimuli and/or episodes of traumatic events may expose the brain to a microenvironment where the non-balanced reactive oxygen species inevitably lead to neuronal loss and cognitive decline. HO-1, a 32 kDa heat-shock protein catalyzing the degradation of heme into carbon monoxide (CO), iron and biliverdin/bilirubin is considered one of the main antioxidant defense mechanisms playing pivotal roles in neuroprotection. Restoring the redox homeostasis is the goal of many natural or synthetic antioxidant molecules pursuing beneficial effects on brain functions. Here, we investigated the antioxidant capacity of four selected benzofuran-2-one derivatives in a cellular model of neurodegeneration represented by differentiated SH-SY5Y cells exposed to catechol-induced oxidative stress. Our main results highlight how all the molecules have antioxidant properties, especially compound 9, showing great abilities in reducing intracellular ROS levels and protecting differentiated SH-SY5Y cells from catechol-induced death. This compound above all seems to boost HO-1 mRNA and perinuclear HO-1 protein isoform expression when cells are exposed to the oxidative insult. Our findings open the way to consider benzofuran-2-ones as a novel and promising adjuvant antioxidant strategy for many neurodegenerative disorders.
Collapse
Affiliation(s)
- Sofia Scibetta
- Department of Medical-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Polo Pontino, 04100 Latina, Italy; (S.S.); (M.I.); (V.P.); (G.R.); (G.M.); (A.C.)
| | - Martina Miceli
- Department of Science, University of Roma Tre, 00146 Rome, Italy; (M.M.); (L.S.)
| | - Marco Iuliano
- Department of Medical-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Polo Pontino, 04100 Latina, Italy; (S.S.); (M.I.); (V.P.); (G.R.); (G.M.); (A.C.)
| | - Luca Stefanuto
- Department of Science, University of Roma Tre, 00146 Rome, Italy; (M.M.); (L.S.)
| | - Elena Carbone
- Department of Neuroscience, Italian National Institute of Health, 00161 Rome, Italy; (E.C.); (P.P.)
| | - Paola Piscopo
- Department of Neuroscience, Italian National Institute of Health, 00161 Rome, Italy; (E.C.); (P.P.)
| | - Vincenzo Petrozza
- Department of Medical-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Polo Pontino, 04100 Latina, Italy; (S.S.); (M.I.); (V.P.); (G.R.); (G.M.); (A.C.)
- Istituto Chirurgico Ortopedico Traumatologico (ICOT), 04100 Latina, Italy
| | - Giovanna Romeo
- Department of Medical-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Polo Pontino, 04100 Latina, Italy; (S.S.); (M.I.); (V.P.); (G.R.); (G.M.); (A.C.)
| | - Giorgio Mangino
- Department of Medical-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Polo Pontino, 04100 Latina, Italy; (S.S.); (M.I.); (V.P.); (G.R.); (G.M.); (A.C.)
| | - Antonella Calogero
- Department of Medical-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Polo Pontino, 04100 Latina, Italy; (S.S.); (M.I.); (V.P.); (G.R.); (G.M.); (A.C.)
- Istituto Chirurgico Ortopedico Traumatologico (ICOT), 04100 Latina, Italy
| | - Tecla Gasperi
- Department of Science, University of Roma Tre, 00146 Rome, Italy; (M.M.); (L.S.)
- National Institute of Biostructures and Biosystems (INBB), 00136 Rome, Italy
| | - Paolo Rosa
- Department of Medical-Surgical Sciences and Biotechnologies, University of Rome Sapienza, Polo Pontino, 04100 Latina, Italy; (S.S.); (M.I.); (V.P.); (G.R.); (G.M.); (A.C.)
- Istituto Chirurgico Ortopedico Traumatologico (ICOT), 04100 Latina, Italy
| |
Collapse
|
2
|
Pandey M, Karmakar V, Majie A, Dwivedi M, Md S, Gorain B. The SH-SY5Y cell line: a valuable tool for Parkinson's disease drug discovery. Expert Opin Drug Discov 2024; 19:303-316. [PMID: 38112196 DOI: 10.1080/17460441.2023.2293158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 12/06/2023] [Indexed: 12/21/2023]
Abstract
INTRODUCTION Owing to limited efficient treatment strategies for highly prevalent and distressing Parkinson's disease (PD), an impending need emerged for deciphering new modes and mechanisms for effective management. SH-SY5Y-based in vitro neuronal models have emerged as a new possibility for the elucidation of cellular and molecular processes in the pathogenesis of PD. SH-SY5Y cells are of human origin, adhered to catecholaminergic neuronal attributes, which consequences in imparting wide acceptance and significance to this model over conventional in vitro PD models for high-throughput screening of therapeutics. AREAS COVERED Herein, the authors review the SH-SY5Y cell line and its value to PD research. The authors also provide the reader with their expert perspectives on how these developments can lead to the development of new impactful therapeutics. EXPERT OPINION Encouraged by recent research on SH-SY5Y cell lines, it was envisaged that this in vitro model can serve as a primary model for assessing efficacy and toxicity of new therapeutics as well as for nanocarriers' capacity in delivering therapeutic agents across BBB. Considering the proximity with human neuronal environment as in pathogenic PD conditions, SH-SY5Y cell lines vindicated consistency and reproducibility in experimental results. Accordingly, exploitation of this standardized SH-SY5Y cell line can fast-track the drug discovery and development path for novel therapeutics.
Collapse
Affiliation(s)
- Manisha Pandey
- Department of Pharmaceutical Sciences, Central University of Haryana, Mahendergarh, India
| | - Varnita Karmakar
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, India
| | - Ankit Majie
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, India
| | - Monika Dwivedi
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, India
| | - Shadab Md
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Bapi Gorain
- Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, India
| |
Collapse
|
3
|
Tyumentseva A, Averchuk A, Palkina N, Zinchenko I, Moshev A, Savchenko A, Ruksha T. Transcriptomic Profiling Revealed Plexin A2 Downregulation With Migration and Invasion Alteration in Dacarbazine-Treated Primary Melanoma Cells. Front Oncol 2021; 11:732501. [PMID: 34926249 PMCID: PMC8677675 DOI: 10.3389/fonc.2021.732501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Accepted: 11/16/2021] [Indexed: 12/02/2022] Open
Abstract
Melanoma is highly heterogeneous type of malignant neoplasm that is responsible for the majority of deaths among other types of skin cancer. In the present study, we screened a list of differentially expressed genes in two primary, drug-naïve melanoma cell lines derived from patients with melanoma following treatment of the cells with the chemotherapeutic agent dacarbazine. The aim was to determine the transcriptomic profiles and associated alterations in the cell phenotype. We found the vascular endothelial growth factor A/vascular endothelial growth factor receptor 2, phosphoinositide 3-kinase/protein kinase B and focal adhesion signaling pathways to be top altered after dacarbazine treatment. In addition, we observed the expression levels of genes associated with tumor dissemination, integrin β8 and matrix metalloproteinase-1, to be diminished in both cell lines studied, the results of which were confirmed by reverse transcription-quantitative polymerase chain reaction. By contrast, plexin A2 expression was found to be upregulated in K2303 cells, where reduced migration and invasion were also observed, following dacarbazine treatment. Plexin A2 downregulation was associated with the promotion of migrative and invasive capacities in B0404 melanoma cells. Since plexin A2 is semaphorin co-receptor that is involved in focal adhesion and cell migration regulation, the present study suggested that plexin A2 may be implicated in the dacarbazine-mediated phenotypic shift of melanoma cells. We propose that the signature of cancer cell invasiveness can be revealed by using a combination of transcriptomic and functional approaches, which should be applied in the development of personalized therapeutic strategies for each patient with melanoma.
Collapse
Affiliation(s)
- Anna Tyumentseva
- Department of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, Russia
- Federal Research Center Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences, Krasnoyarsk, Russia
| | - Anton Averchuk
- Department of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, Russia
| | - Nadezhda Palkina
- Department of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, Russia
| | - Ivan Zinchenko
- Department of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, Russia
| | - Anton Moshev
- Laboratory of Cell Molecular Physiology and Pathology, Federal Research Center, Krasnoyarsk Science Center of The Siberian Branch of The Russian Academy of Sciences, Krasnoyarsk, Russia
| | - Andrey Savchenko
- Laboratory of Cell Molecular Physiology and Pathology, Federal Research Center, Krasnoyarsk Science Center of The Siberian Branch of The Russian Academy of Sciences, Krasnoyarsk, Russia
| | - Tatiana Ruksha
- Department of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, Russia
- *Correspondence: Tatiana Ruksha,
| |
Collapse
|
4
|
Zhang X, Shao S, Li L. Characterization of Class-3 Semaphorin Receptors, Neuropilins and Plexins, as Therapeutic Targets in a Pan-Cancer Study. Cancers (Basel) 2020; 12:cancers12071816. [PMID: 32640719 PMCID: PMC7409005 DOI: 10.3390/cancers12071816] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Accepted: 07/03/2020] [Indexed: 12/19/2022] Open
Abstract
Class-3 semaphorins (SEMA3s), initially characterized as axon guidance cues, have been recognized as key regulators for immune responses, angiogenesis, tumorigenesis and drug responses. The functions of SEMA3s are attributed to the activation of downstream signaling cascades mainly mediated by cell surface receptors neuropilins (NRPs) and plexins (PLXNs), yet their roles in human cancers are not completely understood. Here, we provided a detailed pan-cancer analysis of NRPs and PLXNs in their expression, and association with key signal transducers, patient survival, tumor microenvironment (TME), and drug responses. The expression of NRPs and PLXNs were dysregulated in many cancer types, and the majority of them were further dysregulated in metastatic tumors, indicating a role in metastatic progression. Importantly, the expression of these genes was frequently associated with key transducers, patient survival, TME, and drug responses; however, the direction of the association varied for the particular gene queried and the specific cancer type/subtype tested. Specifically, NRP1, NRP2, PLXNA1, PLXNA3, PLXNB3, PLXNC1, and PLXND1 were primarily associated with aggressive phenotypes, whereas the rest were more associated with favorable prognosis. These data highlighted the need to study each as a separate entity in a cancer type- and subtype-dependent manner.
Collapse
Affiliation(s)
- Xiaoli Zhang
- Department of Biomedical Informatics, College of Medicine, The Ohio State University, 320B Lincoln Tower, 1800 Cannon Dr., Columbus, OH 43210, USA;
- Correspondence:
| | - Shuai Shao
- Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43201, USA;
| | - Lang Li
- Department of Biomedical Informatics, College of Medicine, The Ohio State University, 320B Lincoln Tower, 1800 Cannon Dr., Columbus, OH 43210, USA;
| |
Collapse
|
5
|
Santoro AM, Lanza V, Bellia F, Sbardella D, Tundo GR, Cannizzo A, Grasso G, Arizzi M, Nicoletti VG, Alcaro S, Costa G, Pietropaolo A, Malgieri G, D'Abrosca G, Fattorusso R, García‐Viñuales S, Ahmed IMM, Coletta M, Milardi D. Pyrazolones Activate the Proteasome by Gating Mechanisms and Protect Neuronal Cells from β‐Amyloid Toxicity. ChemMedChem 2019; 15:302-316. [DOI: 10.1002/cmdc.201900612] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Revised: 11/28/2019] [Indexed: 12/18/2022]
Affiliation(s)
- Anna Maria Santoro
- Consiglio Nazionale delle Ricerche Istituto di Cristallografia Via P. Gaifami 18 95126 Catania Italy
| | - Valeria Lanza
- Consiglio Nazionale delle Ricerche Istituto di Cristallografia Via P. Gaifami 18 95126 Catania Italy
| | - Francesco Bellia
- Consiglio Nazionale delle Ricerche Istituto di Cristallografia Via P. Gaifami 18 95126 Catania Italy
| | - Diego Sbardella
- IRCCS – Fondazione G.B. Bietti Via Livenza 3 00189 Roma Italy
- Università di Roma Tor Vergata Dipartimento di Scienze Cliniche e Medicina Traslazionale Via Montpellier 1 00133 Roma Italy
| | - Grazia R. Tundo
- Università di Roma Tor Vergata Dipartimento di Scienze Cliniche e Medicina Traslazionale Via Montpellier 1 00133 Roma Italy
| | - Alessandra Cannizzo
- Università degli Studi di Catania Dipartimento di Scienze Chimiche V.le Andrea Doria 6 95125 Catania Italy
| | - Giuseppe Grasso
- Università degli Studi di Catania Dipartimento di Scienze Chimiche V.le Andrea Doria 6 95125 Catania Italy
| | - Mariaconcetta Arizzi
- Università degli Studi di Catania Dipartimento di Scienze Chimiche V.le Andrea Doria 6 95125 Catania Italy
| | - Vincenzo G. Nicoletti
- Università degli Studi di Catania Dipartimento di Scienze Biomediche e Biotecnologiche (BIOMETEC) Università di Catania Via Santa Sofia 97 95124 Catania
| | - Stefano Alcaro
- Università degli Studi Magna Graecia di Catanzaro Dipartimento di Scienze della Salute Viale Europa 88100 Catanzaro Italy
| | - Giosuè Costa
- Università degli Studi Magna Graecia di Catanzaro Dipartimento di Scienze della Salute Viale Europa 88100 Catanzaro Italy
| | - Adriana Pietropaolo
- Università degli Studi Magna Graecia di Catanzaro Dipartimento di Scienze della Salute Viale Europa 88100 Catanzaro Italy
| | - Gaetano Malgieri
- Università della Campania “Luigi Vanvitelli” Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche Via Vivaldi 43 81100 Caserta Italy
| | - Gianluca D'Abrosca
- Università della Campania “Luigi Vanvitelli” Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche Via Vivaldi 43 81100 Caserta Italy
| | - Roberto Fattorusso
- Università della Campania “Luigi Vanvitelli” Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche Via Vivaldi 43 81100 Caserta Italy
| | - Sara García‐Viñuales
- Consiglio Nazionale delle Ricerche Istituto di Cristallografia Via P. Gaifami 18 95126 Catania Italy
| | - Ikhlas M. M. Ahmed
- Consiglio Nazionale delle Ricerche Istituto di Cristallografia Via P. Gaifami 18 95126 Catania Italy
| | - Massimiliano Coletta
- Università di Roma Tor Vergata Dipartimento di Scienze Cliniche e Medicina Traslazionale Via Montpellier 1 00133 Roma Italy
| | - Danilo Milardi
- Consiglio Nazionale delle Ricerche Istituto di Cristallografia Via P. Gaifami 18 95126 Catania Italy
| |
Collapse
|